KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Capital Leases (2017 - 2025)

Moderna (MRNA) has disclosed Capital Leases for 9 consecutive years, with $20.0 million as the latest value for Q4 2025.

  • Quarterly Capital Leases fell 48.72% to $20.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $20.0 million through Dec 2025, down 48.72% year-over-year, with the annual reading at $20.0 million for FY2025, 48.72% down from the prior year.
  • Capital Leases for Q4 2025 was $20.0 million at Moderna, down from $26.0 million in the prior quarter.
  • The five-year high for Capital Leases was $922.0 million in Q3 2022, with the low at $20.0 million in Q4 2025.
  • Average Capital Leases over 5 years is $458.8 million, with a median of $575.0 million recorded in 2023.
  • The sharpest move saw Capital Leases surged 444.55% in 2021, then plummeted 95.84% in 2025.
  • Over 5 years, Capital Leases stood at $599.0 million in 2021, then surged by 52.25% to $912.0 million in 2022, then plummeted by 36.95% to $575.0 million in 2023, then crashed by 93.22% to $39.0 million in 2024, then crashed by 48.72% to $20.0 million in 2025.
  • According to Business Quant data, Capital Leases over the past three periods came in at $20.0 million, $26.0 million, and $32.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.